ストックスクリーナーアプリを入手
37.29
2.18%
-0.83
Apogee Therapeutics Inc (APGE) 最新ニュース
Apogee Therapeutics (NASDAQ:APGE) Given "Outperform" Rating at Wedbush - MarketBeat
Apogee Therapeutics Faces Supply Chain Risks Amid Geopolitical Tensions and Regulatory Challenges - MSN
Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors - MSN
Apogee Therapeutics (APGE) Is Up 5.9% After Strong APG777 Phase 2 Data and Accelerated Plans - uk.finance.yahoo.com
Apogee Therapeutics Reports Promising Trial Results and Strong Cash Position - TipRanks
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Apogee Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Apogee Therapeutics Q2 2025: A Catalyst-Driven Path to Re-Rating - AInvest
Apogee Therapeutics Q2 Earnings Report: Net Loss of $66.1M, Cash Reserves at $621.2M - AInvest
Apogee Therapeutics stock holds steady as Goldman Sachs reiterates rating - Investing.com
Apogee Therapeutics' APG777: A Pathway to Redefining Atopic Dermatitis Treatment and Long-Term Value Creation - AInvest
Apogee Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Apogee Therapeutics: A High-Potential Biotech Play in Atopic Dermatitis with Best-in-Class Dosing Advantages and Clear Path to Value Creation - AInvest
Apogee Therapeutics provides pipeline progress and reports second quarter 2025 financial results - MarketScreener
Apogee Therapeutics Provides Pipeline Progress And Reports Second Quarter 2025 Financial Results - TradingView
Apogee Therapeutics, Inc. SEC 10-Q Report - TradingView
Apogee Therapeutics Q2 Net Loss Widens - MarketScreener
Apogee Therapeutics Q2 2025 Financial Results and Pipeline Progress - TradingView
Breakthrough: Apogee's New Atopic Dermatitis Drug Achieves 71% Efficacy with 6-Month Dosing Potential - Stock Titan
Apogee Therapeutics APGE Q2 2025 Earnings Preview Upside Potential Hinges on Strategic Partnerships - AInvest
Apogee Therapeutics CMO Carl Dambkowski Sells Shares - TradingView
This Apogee Therapeutics Insider Increased Their Holding In The Last Year - 富途牛牛
Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? - Yahoo Finance
What are the latest earnings results for Apogee Therapeutics Inc.Outstanding capital returns - Jammu Links News
When is Apogee Therapeutics Inc. stock expected to show significant growthDouble or triple returns - Jammu Links News
Is Apogee Therapeutics Inc. a growth stock or a value stockFastest-growing stock picks - Jammu Links News
What is the risk reward ratio of investing in Apogee Therapeutics Inc. stockAchieve consistent profits with proven methods - Jammu Links News
How many analysts rate Apogee Therapeutics Inc. as a “Buy”Maximize your returns with expert insights - Jammu Links News
Is Apogee Therapeutics Inc. a good long term investmentInvest smarter with expert stock picks - Jammu Links News
Should I hold or sell Apogee Therapeutics Inc. stock in 2025Free Stock Selection - Jammu Links News
Is it the right time to buy Apogee Therapeutics Inc. stockAchieve consistent double-digit growth rates - Jammu Links News
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug - MSN
How volatile is Apogee Therapeutics Inc. stock compared to the marketChart Pattern Updates For Fast Growth - Jammu Links News
What’s next for Apogee Therapeutics Inc. stock priceTop Performing Stock Insights Released Daily - metal.it
11 Best Future Stocks to Buy Now - Insider Monkey
Published on: 2025-07-30 23:15:33 - metal.it
Apogee Therapeutics Shares Positive Interim Phase 1b Results for APG808 in Asthma - MSN
Earnings visualization tools for Apogee Therapeutics Inc.Earnings Impact and Stock Reaction Analysis - Newser
Multi Factor Analysis Ranks Apogee Therapeutics Inc. as Strong BuyIntraday Trend Analysis for Fast Gains Released - metal.it
Order Book Volume Tilts Bullish on Apogee Therapeutics Inc.Trade Ready Stock Watch for Short Term Published - metal.it
Is Apogee Therapeutics Inc. stock overvalued or undervaluedFind the best stocks for sustainable growth - Jammu Links News
What makes Apogee Therapeutics Inc. stock price move sharplySolid Return Trade Selections - Newser
Intrinsic Value of Apogee Therapeutics Inc. Stock: Is It Undervalued or OvervaluedFree Elite Traders Group - Newser
What analysts say about Apogee Therapeutics Inc. stockOver 200% growth - PrintWeekIndia
What drives Apogee Therapeutics Inc. stock priceDynamic growth stocks - Autocar Professional
Apogee Therapeutics Inc. Stock Analysis and ForecastBreakthrough capital growth - Autocar Professional
What makes Apogee Therapeutics Inc. stock attractive to long term investorsDynamic growth stocks - Jammu Links News
BofA Securities Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $78 - 富途牛牛
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):